Comparing Genocea Biosciences (NASDAQ:GNCA) & Bluebird Bio (NASDAQ:BLUE)
Comparing Genocea Biosciences (NASDAQ:GNCA) & Bluebird Bio (NASDAQ:BLUE)
Genocea Biosciences (NASDAQ:GNCA – Get Rating) and bluebird bio (NASDAQ:BLUE – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.
基因生物科技(纳斯达克：GNCA-GET评级)和蓝鸟生物(纳斯达克：蓝获得评级)都是小盘医疗公司，但哪一家是优势业务？我们将根据这两家公司的估值、盈利能力、机构所有权、收益、股息、风险和分析师建议的强弱对它们进行比较。
Institutional & Insider Ownership
机构与内部人持股
9.3% of Genocea Biosciences shares are held by institutional investors. Comparatively, 78.3% of bluebird bio shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 2.9% of bluebird bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Genocea Biosciences 9.3%的股份由机构投资者持有。相比之下，蓝鸟生物78.3%的股份由机构投资者持有。Genocea Biosciences 1.6%的股份由公司内部人士持有。相比之下，蓝鸟生物2.9%的股份由公司内部人士持有。强大的机构持股表明，大型基金管理公司、捐赠基金和对冲基金相信，一家公司有望实现长期增长。
Profitability
盈利能力
This table compares Genocea Biosciences and bluebird bio's net margins, return on equity and return on assets.
此表比较了Genocea Biosciences和Bluebird Bio的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Genocea Biosciences | N/A | -182.88% | -62.76% |
| bluebird bio | -2,141.34% | -130.19% | -73.31% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| Genocea生物科学 | 不适用 | -182.88% | -62.76% |
| 蓝鸟传记 | -2,141.34% | -130.19% | -73.31% |
Earnings & Valuation
收益与估值
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Genocea Biosciences | $1.64 million | 0.21 | -$33.20 million | ($0.61) | -0.01 |
| bluebird bio | $3.66 million | 125.80 | -$819.38 million | ($8.32) | -0.72 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| Genocea生物科学 | 164万美元 | 0.21 | -3320万美元 | ($0.61) | -0.01 |
| 蓝鸟传记 | 366万美元 | 125.80 | -8.1938亿美元 | ($8.32) | -0.72 |
Genocea Biosciences has higher earnings, but lower revenue than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.
与蓝鸟生物相比，Genocea Biosciences的收益更高，但收入更低。蓝鸟生物的市盈率低于Genocea Biosciences，表明它目前是两只股票中更负担得起的一只。
Analyst Recommendations
分析师建议
This is a breakdown of recent recommendations and price targets for Genocea Biosciences and bluebird bio, as provided by MarketBeat.
这是MarketBeat提供的Genocea生物科学和蓝鸟生物最近的建议和价格目标的细目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Genocea Biosciences | 0 | 2 | 0 | 0 | 2.00 |
| bluebird bio | 2 | 8 | 1 | 0 | 1.91 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| Genocea生物科学 | 0 | 2 | 0 | 0 | 2.00 |
| 蓝鸟传记 | 2 | 8 | 1 | 0 | 1.91 |
Genocea Biosciences currently has a consensus price target of $3.00, indicating a potential upside of 50,747.46%. bluebird bio has a consensus price target of $8.50, indicating a potential upside of 42.38%. Given Genocea Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Genocea Biosciences is more favorable than bluebird bio.
Genocea Biosciences目前的共识目标价为3.00美元，表明潜在涨幅为50,747.46%。蓝鸟生物的一致目标价为8.50美元，表明潜在涨幅为42.38%。考虑到Genocea Biosciences更高的共识评级和更高的可能上行空间，分析师显然认为Genocea Biosciences比蓝鸟生物更有利。
Risk & Volatility
风险与波动性
Genocea Biosciences has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500.
Genocea Biosciences的贝塔系数为1.76，这表明其股价的波动性比标准普尔500指数高76%。相比之下，蓝鸟生物的贝塔系数为0.97，这表明其股价的波动性比标准普尔500指数低3%。
Summary
摘要
Genocea Biosciences beats bluebird bio on 8 of the 14 factors compared between the two stocks.
Genocea Biosciences在两只股票之间的14个因素中有8个超过了蓝鸟生物。
About Genocea Biosciences
关于Genocea生物科学
(Get Rating)
(获取评级)
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
生物制药公司Genocea Biosciences，Inc.发现和开发新的癌症免疫疗法。该公司使用其专有的发现平台ATLAS，该平台描述了每个患者对下一代肿瘤测序确定的每个目标或抗原的CD4+和CD8+T细胞免疫反应。它的产品包括Gen-011，这是一种过继的T细胞疗法，正处于治疗实体肿瘤的1/2a阶段临床试验；以及Gen-009，它是一种新抗原候选疫苗，正处于1/2a阶段的临床试验，提供跨越ATLAS识别的抗肿瘤新抗原的辅助性合成长肽。该公司成立于2006年，总部设在马萨诸塞州剑桥市。2022年7月5日，Genocea Biosciences，Inc.根据破产法第11章向美国马萨诸塞州地区破产法院提交了自愿重组请愿书。
About bluebird bio
关于蓝鸟传记
(Get Rating)
(获取评级)
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
蓝鸟生物公司是一家生物技术公司，研究、开发和商业化针对严重遗传病的变革性基因疗法。其用于治疗严重遗传性疾病的候选产品包括用于治疗输血依赖型β-地中海贫血的贝替贝吉基因Autotemcel；用于治疗镰状细胞病(SCD)的lovotieglogene autemcel；以及用于治疗大脑肾上腺脑白质营养不良的伊利伐多烯Autotemcel。该公司的临床研究计划包括评估Lovo-cel治疗SCD患者的安全性和有效性的HGB-205、HGB-206和HGB-210；以及评估Beti-cel治疗β-地中海贫血患者的安全性和有效性的HGB-204、HGB-205、HGB-207和HGB-212。它与Orchard治疗有限公司、四十七公司和Magenta治疗公司签订了战略合作和许可协议。该公司前身为Genetix制药公司，并于2010年9月更名为蓝鸟生物公司。蓝鸟生物公司成立于1992年，总部设在马萨诸塞州剑桥市。
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Genocea生物科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Genocea Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。